In this episode of Updates in Anesthesiology, Dr. Hadzic unpacks the latest evidence on sugammadex-induced anaphylaxis from the 2025 Anesthesiology review by Dr. Savic and colleagues. We explore the benefits that make sugammadex the preferred reversal agent over neostigmine, and the rare but serious risk of hypersensitivity reactions. You'll learn about proposed mechanisms, diagnostic pitfalls, global incidence data, and what this all means for your daily anesthesia practice. Stay informed, stay prepared, and make safer clinical choices.

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

Sugammadex: The Reversal Agent with a catch?

Anesthesia Updates

Sugammadex: The Reversal Agent with a catch?